Loading provider…
Loading provider…
Hematology & Oncology Physician in Anaheim, CA
NPI: 1386715365Primary Employer
Southern California Permanente Medical Group
healthy.kaiserpermanente.org
HQ Phone
Mobile
Get MD Ashraf's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1994 - 2026
NJ State Medical License
1996 - 2007
NY State Medical License
1995 - 2006

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Stony Brook Medicine/University Hospital
Fellowship • Hematology and Medical Oncology
1999 - 2002
St John's Episcopal Hospital-South Shore
Residency • Internal Medicine
1996 - 1997
Jamaica Hospital Medical Center
Residency • Internal Medicine
1993 - 1995
New York Downtown Hospital
Internship • Internal Medicine
1992 - 1993
Ain Shams University Faculty of Medicine
Medical School
Until 1988
Hepatocellular carcinoma in an African American man with a noncirrhotic liver presented initially as an occipital mass.
Authors: Maged Khalil, Padjama Sai, Zili He, Ashraf Aziz, William Steier
Authors: Zahir Momin, Yahya Mohammadian
Journal: Clin Adv Hematol Oncol
Authors: Wong, Helen W, Nguyen, Vivian H, Mok, Timothy Y, Niu, Fang, Cushing, Merta, Lam, Michael, Ho, Stephanie L, Law, Lisa, Aziz, Ashraf R, Hui, Rita L
Journal: BioDrugs
Publication Date: 2024-06-27
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, PROCEDURE: Biospecimen Collection, DRUG: Cyclophosphamide, DRUG: Prednisone, DRUG: Vincristine Sulfate, BIOLOGICAL: Rituximab, DRUG: Oral Azacitidine, DRUG: Doxorubicin Hydrochloride
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, BIOLOGICAL: Pegfilgrastim, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, DRUG: Dacarbazine, DRUG: Brentuximab Vedotin, PROCEDURE: Computed Tomography, BIOLOGICAL: Filgrastim, DRUG: Vinblastine Sulfate, DRUG: Doxorubicin Hydrochloride
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Bone Marrow Biopsy, DRUG: Venetoclax, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Ibrutinib, PROCEDURE: Computed Tomography, BIOLOGICAL: Obinutuzumab